Aromatase inhibitors (AIs) block synthesis of oestradiol, the main biologically active oestrogen and ligand for the ER, and are frequently used in treatment of ER+ breast cancer in postmenopausal women [4]. Here, CYP19A1 is linked to breast cancer.